Download PDF
Senologie - Zeitschrift für Mammadiagnostik und -therapie 2020; 17(03): 163-171
DOI: 10.1055/a-1199-2881
Wissenschaftliche Arbeit

Update Mammakarzinom 2020 Teil 2 – fortgeschrittenes Mammakarzinom: neue Substanzen und Einzug diagnostikabhängiger Therapien

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
Diana Lüftner
1   Charité University Hospital, Campus Benjamin Franklin, Department of Hematology, Oncology and Tumour Immunology, Berlin
,
Andreas Schneeweiss
2   National Center for Tumor Diseases, Division Gynecologic Oncology, University Hospital and German Cancer Research Center, Heidelberg
,
Andreas D. Hartkopf
3   Department of Obstetrics and Gynecology, University of Tübingen, Tübingen
,
Volkmar Müller
4   Department of Gynecology, Hamburg-Eppendorf University Medical Center, Hamburg
,
Achim Wöckel
5   Department of Gynecology and Obstetrics, University Hospital Würzburg, Würzburg
,
Wolfgang Janni
6   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm
,
Johannes Ettl
7   Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, Munich
,
Erik Belleville
8   ClinSol GmbH & Co KG, Würzburg
,
Florian Schütz
9   Department of Obstetrics and Gynecology, University of Heidelberg, Heidelberg
,
Marc Thill
10   Agaplesion Markus-Krankenhaus, Frauenklinik, Frankfurt
,
Jens Huober
6   Department of Gynecology and Obstetrics, Ulm University Hospital, Ulm
,
Peter A. Fasching
11   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen
,
Hans-Christian Kolberg
12   Department of Gynecology and Obstetrics, Marienhospital Bottrop, Bottrop
,
Patrik Pöschke
11   Erlangen University Hospital, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen
,
Manfred Welslau
13   Onkologie Aschaffenburg, Aschaffenburg
,
Friedrich Overkamp
14   OncoConsult Overkamp GmbH, Berlin
,
Hans Tesch
15   Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt
,
Tanja N. Fehm
16   Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Düsseldorf
,
Michael P. Lux
17   Klinik für Gynäkologie und Geburtshilfe, Frauenklinik St. Louise, Paderborn, St.-Josefs-Krankenhaus, Salzkotten
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Für Patientinnen mit einem lokal fortgeschrittenen bzw. metastasierten Mammakarzinom wurden in den letzten Jahren neue und effektive Therapien wie CDK4/6-Inhibitoren, PARP-Inhibitoren und ein PD‑L1-Inhibitor eingeführt. In dieser Übersichtsarbeit wird ein Update zu den vorhandenen Studien mit ihrer Datenlage gegeben. Ebenso werden 2 innovative Anti-HER2-Therapien dargestellt (Trastuzumab-Deruxtecan und Tucatinib), für die die Ergebnisse aus neuen Studien berichtet worden sind. Molekulare Tests bieten die Möglichkeit, Patientinnenpopulationen zu definieren oder auch Therapieverläufe zu monitorieren. Dieses kann helfen, Patientinnen mit spezifischen Eigenschaften zu identifizieren, um diesen eine individuelle zielgerichtete Therapie im Rahmen von Studien zukommen zu lassen. In einer großen Studie konnte der Nutzen einer solchen Biomarker-Studie zum ersten Mal beschrieben werden.

Abstract

For patients with locally advanced or metastatic breast cancer, new and effective therapies such as CDK4/6 inhibitors, PARP inhibitors and a PD‑L1 inhibitor have been introduced in recent years. This review presents an update on the available studies with their data. In addition, two innovative anti-HER2 therapies are presented (trastuzumab-deruxtecan and tucatinib) for which the results from new studies have been reported. Molecular tests offer the possibility of defining patient populations or also monitoring courses of therapy. This can help identify patients with specific characteristics in order to provide them with individually targeted therapy within the framework of studies. In a large study, the benefit of such a biomarker study was able to be described for the first time.

Schlüsselwörter

fortgeschrittenes Mammakarzinom - Metastasen - Therapie - Mutationstestung - Immuntherapie - PARP - CDK4/6 - BRCA1/2 - PD‑L1

Key words

advanced breast cancer - metastases - therapy - mutational testing - immune therapy - PARP - CDK4/6 - BRCA1/2 - PD‑L1


Publication History

Article published online:
08 September 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Im SA, Lu YS, Bardia A. et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N Engl J Med 2019; DOI: 10.1056/NEJMoa1903765.
    CrossrefPubMedGoogle Scholar
  • 2 Slamon DJ, Neven P, Chia S. et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA‑3. J Clin Oncol 2018; DOI: 10.1200/JCO.2018.78.9909.
    CrossrefPubMedGoogle Scholar
  • 3 Slamon DJ, Neven P, Chia S. et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. N Engl J Med 2019; DOI: 10.1056/NEJMoa1911149.
    CrossrefPubMedGoogle Scholar
  • 4 Sledge Jr GW, Toi M, Neven P. et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. JAMA Oncol 2019; DOI: 10.1001/jamaoncol. 2019.4782.
    CrossrefPubMedGoogle Scholar
  • 5 Litton JK, Rugo HS, Ettl J. et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med 2018; 379: 753-763
    CrossrefPubMedGoogle Scholar
  • 6 Robson M, Im SA, Senkus E. et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med 2017; 377: 523-533
    CrossrefPubMedGoogle Scholar
  • 7 Andre F, Ciruelos E, Rubovszky G. et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med 2019; 380: 1929-1940
    CrossrefPubMedGoogle Scholar
  • 8 Nakada T, Sugihara K, Jikoh T. et al. The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy. Chem Pharm Bull (Tokyo) 2019; 67: 173-185
    CrossrefPubMedGoogle Scholar
  • 9 Xu Z, Guo D, Jiang Z. et al. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan (DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985). Eur J Med Chem 2019; 183: 111682
    CrossrefPubMedGoogle Scholar
  • 10 Tamura K, Tsurutani J, Takahashi S. et al. Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study. Lancet Oncol 2019; 20: 816-826
    CrossrefPubMedGoogle Scholar
  • 11 Modi S, Saura C, Yamashita T. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med 2019; DOI: 10.1056/NEJMoa1914510.
    CrossrefPubMedGoogle Scholar
  • 12 Murthy RK, Loi S, Okines A. et al. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. N Engl J Med 2019; DOI: 10.1056/NEJMoa1914609.
    CrossrefPubMedGoogle Scholar
  • 13 Murthy R, Borges VF, Conlin A. et al. Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study. Lancet Oncol 2018; 19: 880-888
    CrossrefPubMedGoogle Scholar
  • 14 Rugo HS, Im S-A, Cardoso F. et al. Phase 3 SOPHIA study of margetuximab + chemotherapy vs. trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis. San Antonio Breast Cancer Symposium 2019; GS1-GS02
    PubMedGoogle Scholar
  • 15 Schmid P, Adams S, Rugo HS. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med 2018; 379: 2108-2121
    CrossrefPubMedGoogle Scholar
  • 16 Schmid P, Rugo HS, Adams S. et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2020; 21: 44-59
    CrossrefPubMedGoogle Scholar
  • 17 Chen H, Wu J, Zhang Z. et al. Association Between BRCA Status and Triple-Negative Breast Cancer: A Meta-Analysis. Front Pharmacol 2018; 9: 909
    CrossrefPubMedGoogle Scholar
  • 18 Fasching P, Hu C, Hart S. et al Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics. Cancer Res 2018; 78: PD1-PD02 . doi:10.1158/1538-7445.SABCS17-PD1-02
    CrossrefPubMedGoogle Scholar
  • 19 Diéras V, Han HS, Kaufman B. et al Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer: BROCADE3. Ann Oncol 2019; 30 (Suppl. 05) v851-v934 . doi:810.1093/annonc/mdz1394
    CrossrefPubMedGoogle Scholar
  • 20 Martín M, Zielinski C, Ruíz-Borrego M. et al. Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET) versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). San Antonio Breast Cancer Symposium 2019; 2019: GS2-GS07
    PubMedGoogle Scholar
  • 21 Dowsett M, Sestak I, Regan MM. et al. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol 2018; 36: 1941-1948
    CrossrefPubMedGoogle Scholar
  • 22 Cuzick J, Sestak I, Baum M. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 2010; 11: 1135-1141
    CrossrefPubMedGoogle Scholar
  • 23 Regan MM, Francis PA, Pagani O. et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) HER2-negative breast cancer (BC): Results from TEXT and SOFT. J Clin Oncol 2018; 36: 503
    CrossrefPubMedGoogle Scholar
  • 24 Sparano JA, Gray RJ, Makower DF. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 2018; 379: 111-121
    CrossrefPubMedGoogle Scholar
  • 25 Sestak I, Crager M, Cuzick J. et al. Validation of the clinical treatment score post 5 years (CTS5) in women with hormone receptor positive, HER2-negative, node-negative disease from the TAILORx study. San Antonio Breast Cancer Symposium 2019; 2019: GS4-GS03
    PubMedGoogle Scholar
  • 26 King TA, Liu M, McClure MB. et al. Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network. San Antonio Breast Cancer Symposium 2019; 2019: GS3-GS08
    PubMedGoogle Scholar
  • 27 Radovich M, Jiang G, Chitambar C. et al. Detection of circulating tumor DNA (ctDNA) after neoadjuvant chemotherapy is significantly associated with disease recurrence in early-stage triple-negative breast cancer (TNBC): Preplanned correlative results from clinical trial BRE12-158. San Antonio Breast Cancer Symposium 2019; 2019: GS5-GS02
    PubMedGoogle Scholar
  • 28 Turner N, Kingston B, Kilburn L. et al. Results from the plasma MATCH trial: A multiple parallel cohort, multi-centre clinical trial of circulating tumour DNA testing to direct targeted therapies in patients with advanced breast cancer (CRUK/15/010). San Antonio Breast Cancer Symposium 2019; 2019: GS3-GS06
    PubMedGoogle Scholar
  • 29 Kingston B, Bye H, Hubank M. et al. The genomic landscape of breast cancer based on ctDNA analysis: data from the plasmaMATCH trial. San Antonio Breast Cancer Symposium 2019; 2019: GS3-GS07
    PubMedGoogle Scholar
  • 30 Mobus V, Jackisch C, Luck HJ. et al. Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial. Ann Oncol 2018; 29: 178-185
    CrossrefPubMedGoogle Scholar
  • 31 Blackley EF, Kesper MG, Savas P. et al. Long-term incidence of taxane induced peripheral neuropathy in early breast cancer patients, a real world, single centre experience exploring effects on health related quality of life. San Antonio Breast Cancer Symposium 2019; 2019: P1-17-06
    PubMedGoogle Scholar
  • 32 Ditsch N, Untch M, Thill M. et al. AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel) 2019; 14: 224-245
    CrossrefPubMedGoogle Scholar
  • 33 Leonard RCF, Mansi J, Yellowlees A. et al. Does goserelin have an effect on quality of life in women who have chemotherapy for early breast cancer? Results from the OPTION randomised trial. San Antonio Breast Cancer Symposium 2019; 2019: P2-12-11
    PubMedGoogle Scholar
  • 34 Etaix E, Zheng Y, Rosenberg S. et al. Fertility concerns and treatment decision-making among young women with breast cancer. San Antonio Breast Cancer Symposium 2019; 2019: P2-13-17
    PubMedGoogle Scholar
  • 35 Centers for Medicare & Medicaid Services. Measure Refinements Report for Dry Run: Admissions and Emergency Department (ED) Visits for Patients Receiving Outpatient Chemotherapy. 2017. Online (Stand: 01.04.2020): https://cmit.cms.gov/CMIT_public/ReportMeasure?measureRevisionId=672
    PubMedGoogle Scholar
  • 36 Schilling J, Busch S, Stefek A. et al. Quality of life data of breast cancer patients receiving a fixed combination of netupitant/palonosetron (NEPA) for prevention of chemotherapy-induced nauesa and vomiting – a real life study. San Antonio Breast Cancer Symposium 2019; 2019: P2-12-02
    PubMedGoogle Scholar
  • 37 Aapro M, Schwartzberg L. Efficacy of intravenous (IV) NEPA and oral NEPA, fixed NK1/5-HT3 receptor antagonist combination agents, for prevention of chemotherapy-induced nausea and vomiting (CINV) following anthracycline-cyclophosphamide (AC)-based chemotherapy. San Antonio Breast Cancer Symposium 2019; P2-12-04
    PubMedGoogle Scholar
  • 38 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020; 70: 7-30
    CrossrefPubMedGoogle Scholar